Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, for what reason vosoritide is not available for the treatment of achondroplasia in children.

Voxzogo has not been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA). Should an application for Voxzogo, or any product containing the active ingredient vosoritide, be received, the MHRA will consider this accordingly, with regard to its quality, safety, and effectiveness. It is the responsibility of the company to apply to the MHRA for a marketing authorisation.